Several prominent law firms, including Schall Law Firm and Bronstein, Gewirtz & Grossman, LLC, are investigating Teleflex Incorporated (TFX) for potential fraud. The company's mixed financials may have fueled negative sentiment among investors. For Q1, however, TFX exceeded earnings and revenue estimates. During the BofA Healthcare Conference, Teleflex management delivered a key presentation, available via live webcast. Despite the positive earnings report, Morgan Stanley has maintained its rating but lowered the price target. The First Quarter Revenue was $700.7M, slightly above FactSet expectations. While the company's EPS view for 2025 has been reduced, its stock is up. Jefferies and RBC Capital both adjusted their price target for TFX amid tariff chaos. Meanwhile, Hedge Funds consider it an undervalued asset. The company has cleared FDA expectations for the expanded use of its QuikClot Control+ Device but its investor returns have been trending downwards for the past three years. TFX price cut targets have been reported by Truist Financial and Morgan Stanley. Major sales of TFX shares were also reported by Envestnet Asset Management Inc., JPMorgan Chase & Co., LPL Financial LLC, and Raymond James Financial Inc.
Teleflex Incorporated TFX News Analytics from Tue, 18 Mar 2025 07:00:00 GMT to Fri, 09 May 2025 15:07:10 GMT - Rating -5 - Innovation -3 - Information 5 - Rumor -6
